Castomize's heat-molded 3D-printed orthopedic cast reduces costs by up to 25%

Singapore-based startup Castomize has commercialized a heat-molded 3D-printed orthopedic cast for wrist, arm, and ankle fractures that is breathable, lightweight, and fully waterproof. The device, originating from a 2017 student project at Singapore University of Technology and Design, received medical clearance in Singapore last year and has since gained approval in Australia, South Korea, and Taiwan. Co-founder and CEO Abel Teo reports that in a Singapore hospital trial, the cast delivered average cost savings of 25% compared to traditional fiberglass casts, despite a 30-50% higher per-unit production cost. The company is now pursuing FDA approval in the US and CE marking in Europe, and is developing a sanitization process to enable reuse across multiple patients.

This development updates the recurring pattern of AM-enabled personalized medicine, specifically in the orthopedic and fracture-management segment. Unlike most custom-fit solutions that rely on 3D scanning for each patient, Castomize produces standard sizes and uses post-print heat molding to conform the cast to the individual limb. This approach reduces production time and cost, addressing a key barrier to adoption in cost-sensitive healthcare settings. The device competes with traditional fiberglass and plaster casts, as well as other 3D-printed custom orthoses from companies like ActivArmor and Xkelet. The cost savings from reduced recasting requirements-clinicians can reheat and reapply the same cast if fit issues arise-represent a meaningful operational efficiency for hospitals and clinics, particularly in volume-driven fracture care.

From an expert standpoint, Castomize's model is pragmatic: it avoids the per-patient scanning and design overhead that limits scalability for many custom medical AM applications. The key execution risk is regulatory-securing FDA 510(k) clearance and CE marking will determine whether this approach can scale beyond the Asia-Pacific markets where it is already cleared. The reuse sanitization process, if validated, could further improve the unit economics and make the cast competitive with conventional options on a per-use basis. For now, the company has demonstrated a viable path to cost-effective, mass-customizable fracture care that does not require a full digital workflow for every patient.